case
countri
report
date
mani
patient
becom
critic
ill
report
mortal
among
mer
cov
patient
requir
intens
care
admiss
hospitalbas
outbreak
occur
mainli
ksa
outsid
ksa
south
korea
experienc
second
largest
describ
outbreak
outbreak
origin
singl
index
case
histori
travel
middl
east
spread
sever
acut
care
facil
recent
king
abdulaziz
medic
citi
riyadh
saudi
arabia
experienc
signific
outbreak
led
closur
one
largest
tertiari
care
hospit
countri
depriv
thousand
patient
routin
healthcar
continu
threat
high
mortal
mer
requir
continu
collabor
research
prevent
treatment
diseas
major
burden
mer
seen
saudi
arabia
henc
kingdom
led
design
conduct
nation
intern
collabor
research
mer
goal
identifi
effect
therapi
benefit
patient
across
world
spirit
achiev
goal
king
saud
bin
abdulaziz
univers
health
scienc
king
abdullah
intern
medic
research
center
arrang
mer
research
initi
workshop
took
place
septemb
riyadh
ksa
workshop
collabor
ministri
nation
guard
health
affair
ministri
health
saudi
food
drug
author
nation
intern
expert
meet
includ
preconfer
solicit
topic
includ
expert
attend
without
distinct
government
nongovernment
organiz
academ
privat
industryaffili
particip
identifi
individu
organ
invit
attend
open
meet
spirit
broad
collabor
review
current
state
knowledg
identifi
gap
identifi
promis
import
research
prioriti
improv
care
outcom
patient
mer
broadli
limit
impact
mer
popul
twoday
meet
organ
three
daili
moder
session
consist
present
expert
follow
question
discuss
basic
translat
scienc
diagnost
epidemiolog
infect
prevent
control
drug
biolog
therapeut
research
studi
design
fund
opportun
regulatori
consider
privileg
proprietari
inform
close
session
help
inform
attende
promis
potenti
therapeut
consid
evalu
clinic
trial
publish
unpublish
sourc
workshop
identifi
knowledg
gap
therapeut
nontherapeut
aspect
mer
research
articl
select
topic
present
workshop
includ
issu
journal
infect
public
health
articl
includ
highlevel
perspect
current
statu
drug
develop
clinic
trial
mer
therapi
descript
clinic
spectrum
present
mer
critic
design
clinic
trial
addit
overview
drug
develop
necessari
facil
present
perspect
nation
anim
basic
scienc
heath
laboratori
final
select
promis
product
explor
includ
humanderiv
monoclon
antibodi
nitazoxanid
broadspectrum
antivir
adenosin
nucleosid
analog
acknowledg
therapeut
variou
stage
develop
new
emerg
data
requir
continu
reevalu
therapi
promis
evalu
intent
workshop
accompani
proceed
enhanc
share
rapidli
evolv
basic
clinic
scienc
multidisciplinari
earli
peer
discuss
review
suggest
prioriti
ongo
mer
therapeut
research
fund
sourc
